GS
AZN icon

GTS Securities’s AstraZeneca AZN Stock Holding History

GTS Securities’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,500
Closed -$1.28M – 1368
2026
Q1 		$1.28M Buy
6,500
+5,190
+396% +$1M 0.05% 305
2025
Q4 		$241K Sell
1,310
-10,289
-89% -$1.8M 0.01% 1183
2025
Q3 		$1.78M Sell
11,599
-22,285
-66% -$3.37M 0.07% 231
2025
Q2 		$4.74M Buy
33,884
+31,366
+1,246% +$4.4M 0.21% 76
2025
Q1 		$370K Buy
2,518
+530
+27% +$76.7K 0.02% 850
2024
Q4 		$261K Sell
1,988
-950
-32% -$133K 0.01% 973
2024
Q3 		$458K Sell
2,938
-2,070
-41% -$334K ﹤0.01% 2906
2024
Q2 		$781K Sell
5,008
-29,843
-86% -$4.49M ﹤0.01% 2280
2024
Q1 		$4.72M Buy
+34,851
New +$4.61M 0.01% 902
2023
Q4 		– Sell
-16,868
Closed -$2.19M – 4031
2023
Q3 		$2.28M Buy
+16,868
New +$2.3M ﹤0.01% 1426

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

GTS Securities's AZN Position: Q2 2026 in Review

GTS Securities sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 6,500 shares — an estimated $1.28M sold.

GTS Securities first reported a position in AZN in Q3 2023 and held it in 10 quarters. The position peaked at $4.74M in Q2 2025. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • GTS Securities reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 6,500 AstraZeneca shares in Q2 2026, an estimated $1.28M.
  • GTS Securities first reported a position in AstraZeneca in Q3 2023 and held it in 10 quarters.
  • GTS Securities's AstraZeneca position peaked at $4.74M in Q2 2025.
  • 1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.